How to Monitor for Reglan Tardive Dyskinesia Symptoms

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Awareness to Occupational Exposure

If you or a loved one takes Reglan (metoclopramide) and notices involuntary facial or limb movements, you may be observing early signs of tardive dyskinesia. This condition can develop after long-term use, and recognizing symptoms promptly is critical. Building on decades of pharmacovigilance research, this page provides a clear monitoring guide to help you understand what to watch for and when to consult a healthcare provider.

Find Out If You Qualify for Compensation →

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information advises using Reglan for the shortest duration necessary and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves the drug's dopamine receptor-blocking properties in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. The clinical presentation of TD includes orofacial movements such as lip smacking, chewing, and tongue protrusion, as well as choreiform movements of the limbs and trunk. Diagnosis is based on clinical examination and history of exposure to a dopamine-blocking agent like metoclopramide. The condition may be irreversible even after discontinuation of the drug, and Reglan may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Legal Considerations for Virginia Residents

Regarding the adequacy of warnings, the FDA-mandated boxed warning explicitly states the risk of TD, the importance of short-term use, and the need for immediate discontinuation if signs or symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, patients may have been prescribed Reglan for longer than recommended durations, increasing their risk. The warning also notes that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may not have received adequate information about the risk, particularly if treatment extended beyond 12 weeks. For affected patients in Virginia, settlement considerations involve the statute of limitations for filing a claim. Virginia's statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally two years from the date of injury or from when the injury was discovered or reasonably should have been discovered. The timeline between exposure to Reglan and documented harm is critical. TD may develop after months or years of use, and symptoms may appear after discontinuation. Patients who developed TD after long-term Reglan use may need to establish when they first experienced symptoms or when a diagnosis was made to determine the filing deadline. Settlement-related considerations also include the severity of TD, the duration of Reglan use, and whether the prescribing physician followed the recommended treatment duration. Patients should consult with a legal professional to assess their specific case and ensure timely filing. In summary, Reglan carries a known risk of TD, with the risk increasing with longer use and higher cumulative doses. The FDA label provides clear warnings, but patients may have been exposed beyond recommended durations. For Virginia residents, the statute of limitations requires prompt action after discovery of harm. Legal and medical evaluation is essential to determine eligibility for settlement and to navigate the claims process.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Reglan-related claims in Virginia?

Virginia's statute of limitations for personal injury claims, including those related to prescription drug injuries like Reglan, is generally two years from the date of injury or from when the injury was discovered or reasonably should have been discovered. For tardive dyskinesia, which may develop after months or years of Reglan use, the clock typically starts when symptoms first appear or when a diagnosis is made. It is crucial to consult with a legal professional promptly to determine the applicable deadline for your specific case.

What are the symptoms of tardive dyskinesia caused by Reglan?

Tardive dyskinesia (TD) is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. Common symptoms include lip smacking, chewing, tongue protrusion, grimacing, and choreiform movements of the limbs and trunk. TD may be irreversible even after stopping Reglan, and the drug can suppress signs of TD, potentially delaying diagnosis. If you experience any unusual movements after taking Reglan, seek medical evaluation immediately.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.